Gyre Therapeutics, INC 8-K filings

Gyre Therapeutics held its 2024 Annual Meeting, approving an amendment to its charter to extend exculpation provisions to certain officers and electing directors.

Gyre Therapeutics' subsidiary, Gyre Pharmaceuticals, has received approval from China's National Medical Products Administration for its Investigational New Drug application for F230 tablets to treat pulmonary arterial hypertension.

Gyre Therapeutics announced a 10% increase in sales of ETUARY, a key driver of their Q1 2024 financial results, and provided updates on their clinical development programs.

Gyre Pharmaceuticals, a subsidiary of Gyre Therapeutics, has acquired the rights to generic Nintedanib, a drug competing with their existing product ETUARY, to expand their offerings in the pulmonary fibrosis market.

Gyre Therapeutics has regained compliance with Nasdaq listing rules regarding audit committee composition after appointing a new independent director.

Gyre Therapeutics announced its full year 2023 financial results, highlighting a transformational year with expansion into liver fibrosis and a 13% increase in sales of ETUARY.

Gyre Therapeutics has appointed Rodney Nussbaum, a seasoned financial expert, to its Board of Directors and Audit Committee.

GNI Group Ltd. announced record-high revenue and profit for fiscal year 2023, driven by strong sales of its main product and strategic partnerships, while also detailing progress in its drug development pipeline and recent acquisitions.

Gyre Therapeutics files an amendment to its previous 8-K report, detailing the appointment of a new CEO, the resulting audit committee vacancy, and the terms of the new CEO's employment agreement.

Gyre Therapeutics, formerly Catalyst Biosciences, has filed an amended 8-K report detailing the completion of its business combination with Beijing Continent Pharmaceuticals (BC) and providing pro forma financial statements.